The cost of antiretroviral drug resistance in HIV positive patients

Antiviral Therapy

Volumn 19, Issue 4, 2014, Pages 341-348

  Krentz, Hartmut B ^a,b   Ko, Karen ^a   Beckthold, Brenda ^a   Gill, M John ^a,b  

^a Southern Alberta Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT CARE; PRIORITY JOURNAL; VIRUS LOAD; COST BENEFIT ANALYSIS; DRUG EFFECTS; GENETICS; GENOTYPE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; RISK FACTOR;

ADULT; ALBERTA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84916197981     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2709     Document Type: Article

References (27)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (Accessed 7 September 2012.) Available from http://www.aidsinfo.nih.gov/guidelines/html/1/ adult-and-adolescent-treatment-guidelines/6/drug-resistance-testing
2. European AIDS Clinical Society. Guidelines for the clinical management and treatment of HIV infected adults in Europe. Version 6.0 (Updated October 2011. Accessed 7 September 2012.) http://www.eacsociety.org/Portals/0/files/ pdf%20files/EACSGuidelines-v6.0-English.pdf
3. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008; 47:266-285.
4. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
5. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40:468-474.
6. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41:1316-1323.
7. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
8. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38:723-730.
9. Bansi L, Smith C, Phillips A, et al. The impact of HIV drug resistance testing on changes to treatment. AIDS 2011; 25:603-610.
10. Taylor S, Jayasuriya A, Smit E. Using HIV-1 resistance tests in clinical practice. J Antimicrob Chemother 2009; 64:218-222.
11. Elgalib A, Perry M, Abound M, et al. Clinical utility of genotypic resistance tests for HIV-1 infected patients with low-level virological failure. J Clin Microbiol 2010; 48:3358-3359.
12. Ceccherini-Silberstein F, Cento V, Calvez V, Perno CF. The use of human immunodeficiency virus resistance tests in clinical practice. Clin Microbiol Infect 2010; 16:1511-1517.
13. Paredes R, Cloetet B. Clinical management of HIV-1 resistance. Antiviral Res 2010; 85:245-265.
14. Palella FJ, Jr., Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009; 151:73-84.
15. Krentz HB, Gill MJ. Cost of medical care for HIV infected patients within a regional population from 1997 to 2006. HIV Med 2008; 9:721-730.
16. Lipscomb J, Yabroff KR, Brown ML, et al. Health care costing: data, methods, current applications. Med Care 2009; 47 Suppl 1:S1-S6.
17. Barlow WE. Overview of methods to estimate the medical costs of cancer. Med Care 2009; 47 Suppl 1:S33-S36.
18. Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care 2009; 47 Suppl 1:S82-S88.
19. Krentz HB, Gill MJ. Despite CD4 cell count rebound the higher initial costs of medical care for care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350. AIDS 2010; 24:2750-2753.
20. Buchacz K, Baker R, Ward DJ, et al. Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV Outpatient Study: 1999-2008. Aids Res Treat 2012; 2012:230290.
21. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.
22. von Wyl V, Yerly S, Boni J, et al. Long-term trends of HIV Type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009; 48:979-987.
23. Audelin AM, Lohse N, Obel J, et al. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 2009; 14:995-1000.
24. Uy J, Armon C, Buchacz K, Wood K, Brooks JT. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutation at virologic failure. J Acquir Immune Defic Syndr 2009; 51:450-453.
25. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
26. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:65-72.
27. Beck EJ, Harling G, Gerbase S, DeLay P. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS 2010; 5:215-224.